Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide
- 15 November 1993
- journal article
- Published by Wiley in FEBS Letters
- Vol. 334 (2), 161-164
- https://doi.org/10.1016/0014-5793(93)81704-4
Abstract
The active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)‐dependent proliferation is inhibited by A77 1726 at an effective dose of 30–40 μM. A77 1726 appears to directly inhibit the EGF receptor tyrosine‐specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine‐specific kinase activities.Keywords
This publication has 17 references indexed in Scilit:
- Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionInflammation Research, 1991
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Inhibition of epidermal growth factor‐induced DNA synthesis by tyrosine kinase inhibitorsFEBS Letters, 1990
- Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase InhibitorsScience, 1988
- Monoclonal antibodies to phosphotyrosineJournal of Immunological Methods, 1988
- A thousand and one protein kinasesCell, 1987
- Genistein, a specific inhibitor of tyrosine-specific protein kinases.Journal of Biological Chemistry, 1987
- Kinetic studies of tyrosine kinase inhibition by erbstatin.The Journal of Antibiotics, 1987
- C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity.Journal of Biological Chemistry, 1984
- Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line.Proceedings of the National Academy of Sciences, 1982